WS 1279

Drug Profile

WS 1279

Latest Information Update: 20 Jun 2001

Price : $50

At a glance

  • Originator Fujisawa
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chemotherapy-induced damage

Most Recent Events

  • 20 Jun 2001 No-Development-Reported for Chemotherapy induced damage in Japan (Unknown route)
  • 22 Dec 1994 Preclinical development for Chemotherapy induced damage in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top